Oct 27, 2020   SOURCE: PR NewsWire

COVID-19 Antigen Diagnostic Tests Competitive Landscape with Key Companies

DUBLIN, Oct. 27, 2020 /PRNewswire/ -- The "COVID-19 Antigen Diagnostic Test Landscape" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The global market for COVID-19 Diagnostic Tests was valued at $16B in 2020 and is expected to grow at a CAGR (2020-2025) of 6.5%. The market is segmented into molecular tests, antigen tests, and antibody tests.

Molecular diagnostic tests to diagnose COVID-19 were available in the USA a few months after the outbreak in China. On February 4, 2020, the US FDA issued an emergency use authorization (EUA) enabling the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel. Since then authorized molecular laboratories, molecular diagnostic companies, and in-vitro diagnostic companies have developed several COVID-19 diagnostic tests. The U.S. FDA has authorized more than 262 coronavirus diagnostic tests under EUAs, which include 205 molecular tests, 51 antibody tests, and 6 antigen tests.

This report provides timely coverage and an assessment of the market opportunities for COVID-19 diagnostic tests. The initial demand for antibody tests has subsided due to a shift in the guidance from health authorities to focus on asymptomatic and symptomatic current infection cases. The WHO announced it will provide 120 million rapid COVID-19 tests to low-and middle-income countries. Abbott and Roche have scaled their production of rapid antigen tests and are expected to produce more than 50 million tests per month of BinaxNOWT COVID-19 Ag Card and STANDARD Q SARS-CoV-2 Rapid Antigen Test respectively. Additionally, Point of Care (POC) antigen tests VeritorT Plus System from BD, LumiraDx Sars-CoV-2 Ag from LumiraDx, and Sofia SARS Antigen Test were issued FDA EUA and will augment the rapid testing capabilities at hospitals and near-patient CLIA waived settings.

Combination tests that detect common flu A, B, and COVID-19 are in demand ahead of the flu season. SARS-CoV-2 and influenza A/B test from Roche and Xpert Xpress SARS-CoV-2, influenza A and B, and respiratory syncytial virus (RSV) from Cepheid (Danaher Company) has been issued FDA EUA.

This report provides data and insight for healthtech executives seeking:

    --  Informed decisions for new product development
    --  Evaluation of technology transfer opportunities
    --  Manufacturing and distribution opportunities
    --  Thorough evaluation of the progress of vaccine clinical trials
    --  Competitive landscape assessment

Key Topics Covered:

1 Executive Summary

2 Scope of the Report

3 COVID-19 Antigen Diagnostic Tests Segmentation
3.1 COVID-19 Antigen Diagnostic Tests List (Brief Commentary on Strengths & Weaknesses)
3.2 COVID-19 Antigen Diagnostic Tests by Sample Type

    --  Nasopharyngeal (NP) Swab
    --  Oropharyngeal (OP) Swab
    --  Nasal Swab
    --  Blood
    --  Others

3.3 COVID-19 Antigen Diagnostic Tests by Method

    --  Molecular (PCR) Testing
    --  Antigen-based Testing
    --  Others

3.4 COVID-19 Antigen Diagnostic Tests by Mode of Operation

    --  Point of Care (POC)
    --  Laboratory

4. COVID-19 Antigen Tests Clinical Trials
4.1 by Status
4.2 by Location
4.3 by Sponsor

5. Regulatory Approval
5.1 FDA Approved COVID19 Antigen Tests
5.2 CE Approved COVID19 Antigen Tests

6 COVID-19 Antigen Diagnostic Tests Competitive Landscape (Key Companies)


Companies Mentioned 

    --  Abbott
    --  Abbott Diagnostics Scarborough, Inc.
    --  Access Bio, Inc
    --  AmonMed Biotechnology Co., Ltd
    --  AMS UK Ltd.
    --  Apollo Biomedical LLC
    --  ArcDia International Ltd.
    --  Becton, Dickinson and Company (BD)
    --  Beijing Abace Biology Co. Ltd
    --  Beijing Diagreat Biotechnologies Co., Ltd
    --  Beijing Kewei Clinical Diagnostic Reagent Inc.
    --  Beijing Savant Biotechnology Co., Ltd
    --  BIOHIT HealthCare (Hefei) Co., Ltd
    --  Bionote Inc.
    --  Boditech Inc.
    --  Cepheid
    --  CerTest Biotec S.L.
    --  Coris BioConcept
    --  DiaSorin
    --  Edinburgh Genetics Limited
    --  GenBody, Inc.
    --  Green Cross Medical Science Corp.
    --  Hangzhou Deangel Biological Engineering Co., Ltd
    --  Hangzhou Genesis Biodetection & Biocontrol Co., Ltd
    --  Hologic
    --  Humasis
    --  Jiangsu Bioperfectus Technologies Co. Ltd
    --  JOYSBIO (Tianjin) Biotechnology Co., Ltd
    --  Liming Bio-Products Co., Ltd
    --  LumiQuick Diagnostics Inc.
    --  LumiraDx UK Ltd.
    --  Medisys International SA
    --  nal von minden GmbH
    --  PCL Inc.
    --  Precision Biosensor, Inc.
    --  Qiagen
    --  Quidel Corporation
    --  RapiGEN Inc.
    --  Roche
    --  SD BIOSENSOR, Inc.
    --  Shenzhen Bioeasy Biotechnology Co., Ltd
    --  ThermoFisher

For more information about this report visit https://www.researchandmarkets.com/r/lsxr83

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/covid-19-antigen-diagnostic-tests-competitive-landscape-with-key-companies-301160916.html

SOURCE Research and Markets